These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33960119)

  • 21. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
    Shen YC; Wang HJ; Lee WC; Chen CH; Chuang YC
    Int J Clin Pract; 2020 Sep; 74(9):e13537. PubMed ID: 32438481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
    Inoue M; Yokoyama T
    Acta Med Okayama; 2019 Oct; 73(5):387-392. PubMed ID: 31649364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
    Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
    Wang CC; Lee CL; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
    Jiang YH; Liao CH; Tang DL; Kuo HC
    PLoS One; 2014; 9(8):e105989. PubMed ID: 25148378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?
    Balachandran A; Curtiss N; Basu M; Duckett J
    Int Urogynecol J; 2015 Mar; 26(3):367-72. PubMed ID: 25030325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.
    Illiano E; Finazzi Agrò E; Natale F; Balsamo R; Costantini E
    Int Urol Nephrol; 2020 Jun; 52(6):1035-1042. PubMed ID: 32086713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study.
    Švabík K; Mašata J; Krhut J; Zachoval R; Hanuš T; Halaška M; Martan A
    Ceska Gynekol; 2018; 83(3):164-168. PubMed ID: 30764614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
    J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
    Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
    Kakizaki H; Lee KS; Katou D; Yamamoto O; Sumarsono B; Uno S; Yamaguchi O
    Adv Ther; 2021 Jan; 38(1):739-757. PubMed ID: 33245533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.
    Shin JH; Choo MS
    Low Urin Tract Symptoms; 2019 May; 11(3):151-157. PubMed ID: 30623583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.
    Liao CH; Kuo HC
    Medicine (Baltimore); 2016 Nov; 95(45):e4962. PubMed ID: 27828840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Vecchioli Scaldazza C; Morosetti C
    Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
    Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.